Brain Tumor Centers

Find U.S. facilities with actively recruiting interventional brain-tumor trials. Choose one state at a time; facility details load only after you select a facility.

Back to facilities in Washington

Seattle Children's Hospital

Seattle, Washington 98105

Reported site contacts

Andras Heczey, MD — contact
andras.heczey@seattlechildrens.org
Trial: NCT07148050

Christian L Roth, MD — principal investigator
Trial: NCT06299891

Daniel Runco, MD, MS — contact
daniel.runco@seattlechildrens.org
206-987-5783
Trial: NCT07346157

Erin Crotty, MD — contact
erin.crotty@seattlechildrens.org
206-987-2106
Trial: NCT05009992

Erin Crotty, MD — contact
erin.crotty@seattlechildrens.org
2069872106
Trial: NCT05843253

Erin Crotty, MD — contact
erin.crotty@seattlechildrens.org
206-987-2106
Trial: NCT06161974

Erin Crotty, MD — contact
erin.crotty@seattlechildrens.org
206-987-2106
Trial: NCT06838676

Erin Crotty, MD — contact
erin.crotty@seattlechildrens.org
626-319-5760
Trial: NCT07346157

HemOnc Clinic — contact
hemonccras@seattlechildrens.org
206-987-2106
Trial: NCT07680439

Michelle Choe, MD — principal investigator
Trial: NCT07148050

Michelle Choe, MD — contact
michelle.choe@seattlechildrens.org
206-987-2106
Trial: NCT07148050

Nick Vitanza, MD — contact
cbdcintake@seattlechildrens.org
206-987-2106
Trial: NCT04185038

Rebecca Ronsley, MD — principal investigator
Trial: NCT04185038

Rebecca Ronsley, MD, FRCPC — contact
rebecca.ronsley@seattlechildrens.org
206-987-2106
Trial: NCT05233397

Sarah E. Leary — principal investigator
Trial: NCT04166409

Sarah E. Leary — principal investigator
Trial: NCT04684368

Sarah E. Leary — principal investigator
Trial: NCT05099003

Sarah E. Leary — principal investigator
Trial: NCT05382338

Sarah Leary, MD — contact
sarah.leary@seattlechildrens.org
206-987-2106
Trial: NCT04655404

Sarah Leary, MD — principal investigator
Trial: NCT05096481

Sarah Leary, MD — contact
sarah.leary@seattlechildrens.org
206-987-2106
Trial: NCT05096481

Sarah Leary, MD — principal investigator
Trial: NCT07680439

Site Public Contact — contact
866-987-2000
Trial: NCT04166409

Site Public Contact — contact
866-987-2000
Trial: NCT04684368

Site Public Contact — contact
866-987-2000
Trial: NCT05099003

Site Public Contact — contact
866-987-2000
Trial: NCT05382338

Stephanie Purdy — contact
stephanie.purdy@seattlechildrens.org
206-987-2540
Trial: NCT06299891

Recruiting trials at this facility

• A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion (NCT04655404)
  High Grade Glioma, Diffuse Intrinsic Pontine Glioma
• A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT (NCT04684368)
  Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma, Immature Teratoma, Malignant Teratoma, Mixed Germ Cell Tumor, Pineal Region Germ Cell Tumor, Pineal Region Immature Teratoma, Pineal Region Yolk Sac Tumor, Suprasellar Germ Cell Tumor
• A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) (NCT05099003)
  Malignant Glioma
• A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma (NCT04166409)
  Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Astrocytoma, Metastatic Low Grade Glioma, WHO Grade 1 Glioma, WHO Grade 2 Glioma
• A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss (NCT05382338)
  Childhood Medulloblastoma
• A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors (NCT04775485)
  Low-grade Glioma, Advanced Solid Tumor
• ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas (NCT06838676)
  Diffuse Intrinsic Pontine Gliomas (DIPG), Progressive DIPG, Refractory DIPG, Recurrent DIPG, H3K27-altered High Grade Glioma
• ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma (NCT05233397)
  Adamantinomatous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
• Combination Therapy for the Treatment of Diffuse Midline Gliomas (NCT05009992)
  Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent WHO Grade III Glioma, WHO Grade III Glioma
• Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity (NCT06299891)
  Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma
• Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG). (NCT07680439)
  Diffuse Intrinsic Pontine Glioma, DIPG, Brain Tumor, CNS Tumor, Central Nervous System Tumor, Pediatric Cancer, Adult Cancer Patients, CNS Tumor, Childhood, CNS Tumor, Adult, Brainstem Glioma, Diffuse Midline Glioma, DMG
• Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells (NCT07148050)
  Solid Tumor (Excluding CNS), Liver Cell Carcinoma, Malignant Rhabdoid Tumor, Yolk Sac Tumor, Liposarcoma, Rhabdomyosarcoma, Embryonal Sarcoma of Liver, Wilms Tumor, Hepatocellular Carcinoma, Hepatoblastoma
• Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease (NCT07346157)
  Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent
• PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma (NCT05096481)
  High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma
• Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors (NCT04185038)
  Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, Ependymoma, Medulloblastoma, Childhood, Germ Cell Tumor, Atypical Teratoid/Rhabdoid Tumor, Primitive Neuroectodermal Tumor, Choroid Plexus Carcinoma, Pineoblastoma, Childhood, Glioma
• Study of Olutasidenib and Temozolomide in HGG (NCT06161974)
  High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO Grade III Glioma, WHO Grade IV Glioma, Metastatic Brain Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Thalamus Tumor, Spinal Tumor, IDH1 Mutation, IDH1 R132, IDH1 R132C, IDH1 R132H, IDH1 R132S, IDH1 R132G, IDH1 R132L, Oligodendroglioma
• Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant (NCT05843253)
  High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Brain Tumor, WHO Grade III Glioma, WHO Grade IV Glioma, Diffuse Hemispheric Glioma, H3 G34-Mutant